Drug Profile


Alternative Names: Anti-CTGF antibody; FG-3019

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator FibroGen
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Pancreatic cancer
  • Phase I Glomerulonephritis
  • Preclinical Glioblastoma
  • Discontinued Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies

Most Recent Events

  • 03 Feb 2017 Updated efficacy data from a phase I/II trial in Pancreatic cancer (Combination therapy, Late-stage disease) released by FibroGen
  • 20 Jan 2017 Efficacy and adverse events data from a phase I/II trial in Pancreatic cancer (Second-line therapy or greater, Combination therapy) released by Fibrogen
  • 12 Aug 2016 FibroGen terminates phase II trial in Hepatic fibrosis in Hong Kong (NCT01217632)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top